MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, marking a step toward commercializing voice-based impairment detection technology for workplace safety. The kiosks analyze short voice samples for over 140 acoustic markers associated with alcohol, drug, or fatigue-related impairment, using models trained on more than 50 million data points.
The prototypes are entering testing, validation, and data-analysis phases involving industry participants, speech specialists, and software engineers as the company refines its predictive models and assesses real-world performance. MindBio targets safety-sensitive industries including mining, aviation, construction, transportation, and law enforcement, where large workforces and operational risks make conventional breath, saliva, urine, and laboratory testing costly and time-consuming.
The company's approach provides rapid, scalable, and less invasive initial screening, with individuals flagged for potential impairment able to undergo additional evaluation using established testing protocols. As noted in the full announcement available at https://ibn.fm/R2OqM, the technology aims to address the limitations of current methods.
MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy using the human voice. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in environments such as mining, aviation, construction, and law enforcement.
For more information, visit the company's website at www.MindBioTherapeutics.com. The latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
